In a subsequent clinical trial, two patients (one SCD, one TDT) received autologous CD34+ HSCs, edited with CRISPR-Cas9 after myeoloabative conditioning, resulting in high levels of allelic disruption and HbF expression. The gene discussed is CD34; the disease is Schnyder corneal dystrophy.